(Q53432205)

English

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.

scientific article published in April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Su Jin Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Chul Won Jung

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Dae-Young Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Kyoo-Hyung Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Sang Kyun Sohn

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Jae-Yong Kwak

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Hyeoung-Joon Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

In Ho Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Seonyang Park

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Dong Hwan Dennis Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

86

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

346-350

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Applying the discovery of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.21980

21 January 2018

Identifiers

10.1002/AJH.21980

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21442637

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53432205&oldid=1584489347"